Brief: Sino Biopharmaceutical Says New Indication Of TDI01 Suspension ("Rock2 Inhibitor") Included In Breakthrough Therapy Designation Process By CDE
16/06/2025 11:11
June 16 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK:
NEW INDICATION OF TDI01 SUSPENSION ("ROCK2 INHIBITOR") INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS BY CDE
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit